93 results about "Ivabradine" patented technology

The invention relates to a novel method for preparing angina pectoris medicine Ivabradine (compound I and salt thereof). The method takes a formula II compound as the raw material to obtain a compound III through catalytic hydrogenation, the compound III is made an alkylation reaction with a formula IV compound to produce the compound I. The method is simple and convenient, is easy to obtain raw materials, and is suitable for industrialized production.

Process for the synthesis of the compound of formula (I):

Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof.

The subject-matter of the present invention is a novel, non-salified ivabradine solid form, in particular an ivabradine form adsorbed on an inert carrier. The subject-matter of the invention is also a process for preparing said solid form, its use in therapy and pharmaceutical compositions comprising it.

The invention relates to a method for synthesizing Ivabradine or salts thereof, which is prepared by two steps of synthesizing an intermediate N-(3-substitutedpropyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-ketone by 7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-ketone, and further reacting with (1S)-4,5-dimethoxy-1-[(methylamino)methyl] benzocyclobutane. By using the method in the invention for preparing the Ivabradine or salts thereof, the reaction post-treatment is simple, the product purity is high, the yield is high, and the method is favor of industrialized production.

The invention relates to a pharmaceutical composition for preventing or treating patients with myocardial ischemic chronic heart failure and an application thereof. Active components of the composition are composed of ivabradine and clopidogrel or its pharmaceutically acceptable salts, wherein the pharmaceutically acceptable salts are bisulfate, sulfate, camphorsulfonate and hydrochloride. The western medicinal compound provided by the invention can be used to cooperatively treat patients with myocardial ischemic chronic heart failure and simultaneously reduce adverse effects of the medicine.

A composite medicine in the form of tablet, capsule, dispersing tablet, slow-release tablet, or slow-release capsule for preventing and treating myocardial ischemia contains Yifabuleiding and nitrate medicine as synergist.

The invention relates to the technique field of a preparation method of an intermediate compound of Ivabradine. The preparation method of 3-(3-chloropropyl)-7, 8-dimethoxy-1, 3-dihydro-2H-3-benazepine-2-ketone comprises: making 7, 8-dimethoxy-1, 3-dihydro-2H-3-benazepine-2-ketone and 1, 3-chlorobromide have the alkylation reaction. The preparation method unexpectedly selects an alkaline reagent used commonly, and has advantages of mild reaction conditions, safety and reliability, and rather high yield, and the method fully overcomes the defects of strong water absorption, easy deterioration, or easy explosion under rather low temperature of the alkylation reagent used in the prior art, and is extremely applied to the industrialized big-production.

The invention discloses a preparation method for ivabradine impurities. According to the preparation method, 3-hydroxy-4-methoxyphenylacetic acid (as shown in a formula 1a) and 4-hydroxy-3-methoxyphenylacetic acid (as shown in a formula 1b) are respectively used as a starting raw material and subjected to multiple steps of reactions to prepare two impurities of ivabradine. The preparation method of the invention is simple and realizes high-purity preparation; and the prepared impurities can be used for qualitative and quantitative analysis so as to improve the medication safety of ivabradine.

The invention discloses a preparation method for Ivabradine. Catalytic hydrogenation is carried out on a formula (II) compound to obtain a formula (III) compound, reaction is carried out between the formula (III) compound and a formula (IV) compound under the action of base catalysis, and a catalyst is removed through filtration and separated to obtain the target compound.

The invention provides a preparation method for ivabradine and an intermediate thereof dehydrogenated ivabradine. The preparation method of the dehydrogenated ivabradine comprises: step a1, enabling a compound shown as a formula II and a compound shown as a formula III to have a nucleophilic substitution reaction in a polar aprotic solvent in the presence of an acid binding agent and a composite phase-transfer catalyst to generate dehydrogenated ivabradine; and step b1, performing separation and purification on dehydrogenated ivabradine obtained in the step a1. The composite phase-transfer catalyst is composed of a quaternary ammonium salt phase-transfer catalyst and a polyether phase-transfer catalyst with the mass ratio of 1-10:1, and X in the formula II is selected from Cl, Br, I, sulfonyloxy, methane sulfonyloxy, benzene sulfonyloxy, p-methylbenzene sulfonyloxy, o-methylbenzene sulfonyloxy or m-methylbenzene sulfonyloxy. The method is capable of substantially shortening the time of nucleophilic substitution reaction, improving product purity, avoiding a column chromatography process and reducing production cost.

The invention provides a set of intermediate compounds used for synthesis of Ivabradine and a preparation method thereof, and also provides a method used for synthesizing Ivabradine from the intermediate compounds. According to the method, the set of intermediate compounds are subjected to a plurality of N alkylation or N acylation so as to obtain a compound IV; and Ivabradine is directly synthesized from the compound IV. The method is short in synthesis route; raw materials are simple and easily available; reaction sequence is reasonable; operation is simple and high in efficiency; the method is green and friendly to the environment; synthesis difficulty of Ivabradine is reduced greatly; cost is low; product yield is high; and the method is suitable for industrialization production.

The invention relates a novel synthetic method of ivabradine and a novel intermediate product of the ivabradine. In consideration of huge medicinal value of the ivabradine (compound I) and larger difficulty for synthesizing the ivabradine at present, the invention provides a group of novel benzocyclobutane compounds and a method for synthesizing the benzocyclobutane compounds and a method for synthesizing the ivabradine by the benzocyclobutane compounds, that is, a novel synthetic method of the ivabradine. The method provided by the invention is short in synthetic line, simple to operate, simple in preparation method and low in cost, and the synthetic difficulty of the ivabradine is greatly reduced.

The invention provides a medical composition containing ivabradine or pharmacologically acceptable salts and ranolazine or pharmacologically acceptable salts thereof. Proved by research, the medical composition effectively relieves myocardial ischemia and has good synergetic effect on myocardial ischemia diseases, such as angina, coronary heart disease, and the like by the combined use of the ivabradine and the ranolazine. Thus, a method for treating myocardial ischemia diseases with good effect and low adverse reaction is found. The invention finds a good solution for treating myocardial ischemia diseases clinically with poor effect at present.

The invention relates to an ivabradine preparation or an ivabradine medicinal salt solid preparation and a preparation method thereof. The preparation comprises ivabradine or ivabradine medicinal salt nanocapsules and a medicinal auxiliary material, wherein the mass ratio of the ivabradine or the ivabradine medicinal salt to a carrier material is 5-15:1; the carrier material is a composition prepared from xanthan, silk fibroin and aerosil; and the mass ratio of the xanthan to the silk fibroin to the aerosil is 1.5-4.5:1:1. The optimization proportions of the xanthan, the silk fibroin and the aerosil, melting temperature, heat preservation measure and the effects of various factors on the preparation are selected so as to determine an optimized preparation condition and achieve an entrapment rate of over 95 percent; and the preparation has the advantages of preventing medicament burst release, reducing adverse reactions, improving the compliance of patients and overcoming side effects such as dosage dependence, visual symptoms and the like.

The invention provides one group of novel benzene cyclobutane compounds, a method for preparing the novel benzene cyclobutane compounds and a method for preparing ivabradine from the novel benzene cyclobutane compounds for solving the problems of higher synthesis difficulty in the ivabradine with huge medicinal value at present. The invention provides a preparation method for the ivabradine. The method is short in synthetic path and is simple to operate so that the synthesis difficulty of the ivabradine is greatly reduced; and in addition, the method has the advantages of low cost, high yield of products and favorable industrial base and application value.

The invention discloses a preparation method for ivabradine. The method includes: in the presence of a noble metal catalyst and a hydrogen transfer reagent, subjecting 3-3{-[{[(7S)-3, 4-dimethoxy benzocyclobutene-7-]methyl}(methyl)amino-propyl]- 7, 8-dimethoxy-1, 3-dihydro-2-hydro-3-benzoazepine-2-one to hydrogen transfer reaction, and after complete reaction, conducting aftertreatment to obtain the ivabradine. The method provided by the invention avoids strict requirements for equipment in hydrogenation reaction, also effectively reduces side effect, and increases the reaction yield.

The invention belongs to the technical field of the medicine, and specifically relates to a demethylivabradine salt as well as a preparation method and an application thereof. The demethylivabradine salt is a pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt includes citrate, hydrobromide, sulfate, phosphate, acetate, trifluoroacetate, lactate, acetonate, malonate, succinate, glutarate, fumarate, maleate, ascorbate, oxalate, mesylate, benzene sulfonate and camphorate, and has excellent stability and solubility, and also has low hygroscopicity and remarkable advantages.

Preparing an optically pure (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid compound (I), comprises enantioselective enzymatically esterifying a racemic acid or 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid (a), using a lipase or esterase, in a mixture of an alcohol and an organic cosolvent, at a temperature of 25-40[deg] C, where (a) is not pure, has a concentration of 5-500 g/l, and has an enzyme/substrate (E/S) ratio of 10/1:1/100. Preparing an optically pure (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid compound (I), comprises enantioselective enzymatically esterifying a racemic acid or 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid (a), using a lipase or esterase, in a mixture of an alcohol of formula (ROH) and an organic cosolvent, at a temperature of 25-40[deg] C, where (a) is not pure, has a concentration of 5-500 g/l, and has an enzyme/substrate (E/S) ratio of 10/1:1/100. R : linear or branched 1-6C-alkyl, preferably methyl. Independent claims are included for: (1) process-II for preparing an optically pure compound of formula (S)3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid compound of formula (II) by enantioselective enzymatic hydrolysis of the racemic ester or ester compound of formula (b) using the lipase or esterase, in water and in a buffer solution of pH 5-8 or in a mixture of organic solvent and water or buffer at a temperature of 25-40[deg] C, where (b) is not pure, and has E/S ratio of 10/1:1/100; and (2) process-III for preparing ((S)-3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-ylmethyl)-methyl-amine compound (III) comprising either hydrolyzing 3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile (IV) to form (a), enzymatically esterifying (a) to form (I), converting (I) into an optically pure (S)-3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid methylamide amide (c) and reducing (c), or hydrolyzing (IV) to form (a), alkylating (a) to form (b), enzymatically hydrolyzing (b) to obtain (II), converting (II) into (c), and reducing (c). [Image].